Junning Lee

Junning Lee discloses dealings in 2 companies, chiefly Innoviva, Inc. and Theravance Biopharma, Inc. We count 26 filings; the first trade dates from 23 January 2014 and the latest from 20 February 2017.

On the open market, the record shows 1 purchase worth €105k and 1 sale worth €899k. Taken together, the sales exceed the purchases by €794k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 20 share grants and 4 option exercises.

The record was last updated on 22 February 2017 with a share grant (€306k) in Theravance Biopharma, Inc. The clock since the last published purchase (18 August 2015) now reads 4,101 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.